1. The alpha 2-adrenoceptor agonist
clonidine elicits centrally mediated effects through an interaction with both alpha 2-adrenoceptors and
imidazoline binding sites. 2. We selected a new oxazoline derivative,
S 8350, which competes with [3H]-
yohimbine for binding to cerebral alpha 2-adrenoceptors (IC50, 67 +/= 17 nmol/L) and displays a higher affinity (35-fold) for alpha 2- than for alpha 1-adrenoceptors. 3. As observed for
clonidine, intravenous (i.v.) administration of
S 8350 resulted in a brief pressor effect followed by a prolonged
hypotension. When
S 8350 was administered i.v. to spinally pithed rats, only a rise in blood pressure was observed. 4. In order to discriminate the cardiovascular effects related to the central
imidazoline receptor or alpha 2-adrenoceptor activation, the effects of intracisternal (i.c.) administration of
clonidine and
S 8350 were investigated in the rat. 5. In the anaesthetized rat, both
clonidine and
S 8350 displayed a profound central (i.c. route) hypotensive effect associated with a
bradycardia. 6. The cardiovascular effects of
S 8350 were abolished by the central administration of the selective alpha 2-adrenoceptor antagonist
rauwolscine. Conversely,
rauwolscine completely prevented
bradycardia but it induced only a partial reversion of the
hypotension elicited by
clonidine. 7. These results suggest that central alpha 2-adrenoceptors are responsible for
hypotension and
bradycardia while
imidazoline binding sites do not apparently contribute to heart rate control.